• Medientyp: E-Artikel
  • Titel: Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
  • Beteiligte: Zattarin, Emma; Presti, Daniele; Mariani, Luigi; Sposetti, Caterina; Leporati, Rita; Menichetti, Alice; Corti, Chiara; Benvenuti, Chiara; Fucà, Giovanni; Lobefaro, Riccardo; Ligorio, Francesca; Provenzano, Leonardo; Vingiani, Andrea; Del Vecchio, Marta; Griguolo, Gaia; Sirico, Marianna; Bernocchi, Ottavia; Marra, Antonio; Zagami, Paola; Agostinetto, Elisa; Jacobs, Flavia; Di Mauro, Pierluigi; Esposito, Andrea; Giorgi, Carlo Alberto; [...]
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: npj Breast Cancer
  • Sprache: Englisch
  • DOI: 10.1038/s41523-023-00534-1
  • ISSN: 2374-4677
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.</jats:p>
  • Zugangsstatus: Freier Zugang